Currently, there are several anti-CXCL10 monoclonal antibodies and anti-CXCR3 molecule blockades that are being investigated in clinical trials for autoimmune diseases such as rheumatoid arthritis [37]; however, the therapeutic efficacies of these antagonists in vitiligo patients are currently unknown. The gene discussed is CXCR3; the disease is autoimmune disease.